Biodexa Pharmaceuticals (BDRX) Invested Capital (2015 - 2025)

Biodexa Pharmaceuticals (BDRX) has 11 years of Invested Capital data on file, last reported at $5.6 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital rose 612.01% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $6.3 million (up 540.21% YoY), and the FY2025 full-year result was $5.5 million, up 605.77% from the prior year.
• Invested Capital rose to $5.6 million in Q4 2025, from $781652.6 in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $5.6 million in Q4 2025 to a low of $209754.7 in Q4 2023.
• A 5-year average of $1.8 million and a median of $831606.2 in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital slumped 74.78% in 2023 and jumped 612.01% in 2025, its largest moves.
• Tracing BDRX's Invested Capital over 5 years: stood at $1.8 million in 2021, then sank by 53.23% to $831606.2 in 2022, then tumbled by 74.78% to $209754.7 in 2023, then surged by 272.65% to $781652.6 in 2024, then surged by 612.01% to $5.6 million in 2025.
• Business Quant data shows BDRX's Invested Capital at $5.6 million in Q4 2025, $781652.6 in Q4 2024, and $209754.7 in Q4 2023.